Gp-ASIT is under clinical development by DMS Imaging and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Gp-ASIT’s likelihood of approval (LoA) and phase transition for Allergic Rhinitis took place on 04 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Gp-ASIT Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Grass pollen-derived peptides (gpASIT with TM) are under development for the treatment of seasonal grass pollen-induced rhino conjunctivitis and hay fever (allergic rhinitis). The drug candidate is a peptide hydrolysate derived from Lolium perenne. It is administered orally and subcutaneously.
DMS Imaging overview
DMS Imaging, formerly ASIT Biotech SA, is a medical device manufacturing company. It designs and manufactures diagnostic medical imaging solutions in radiology, bone densitometry, stereo-radiography and posturology. The company’s product portfolio includes chest and bone rooms, retrofit kits, 3D reconstruction, radiology equipment, ultrasound bone densitometers and x-ray bone densitometers. DMS Imaging radiology equipment comprises mobile radiology units, floating panel tables and mobile c-arm. It also provides installation and maintenance services. The company offers products under the brands Apelem, DMS, AXS Medical, Medilink and BIOMOD. It provides services through its distributors across the world. DMS Imaging is headquartered in Liege, Belgium.
Quick View Gp-ASIT LOA Data
|Highest Development Stage|